Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fleischhacker

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
Neuroscience|May 30, 2001
Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatmentJ Marksteiner, U Weiss, C Weis, et al.
Biological Psychiatry|June 1, 1996
CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin)C Miller, R Kirchmair, J Troger, et al.
European Journal of Haematology|August 31, 2000
EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparisonM Kopp, H Schweigkofler, B Holzner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 30, 2001
Use of alternative/complementary therapy in breast cancer patients--a psychological perspectiveR Moschèn, G Kemmler, H Schweigkofler, et al.
Pharmacopsychiatry|March 1, 2007
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapineA Hofer, M A Rettenbacher, M Edlinger, et al.
Journal of Neurochemistry|September 13, 2003
Differential effects of phencyclidine application on secretogranin II expression in organotypic slices of rat prefrontal cortexJosef K Hinterhoelzl, Kayvon Salimi, Christian Humpel, et al.
Psychological Medicine|April 18, 2013
Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosisA Riecher-Rössler, J K Rybakowski, M O Pflueger, et al.
The American Journal of Psychiatry|October 2, 2001
Association of olanzapine-induced weight gain with an increase in body fatU Eder, B Mangweth, C Ebenbichler, et al.
Journal of Clinical Psychopharmacology|August 1, 1994
A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatientsC H Stuppaeck, C Geretsegger, A B Whitworth, et al.
International Journal of Clinical Practice|July 14, 2007
Metabolic side effects of antipsychotic medicationA Tschoner, J Engl, M Laimer, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
Neuroscience|May 30, 2001
Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatmentJ Marksteiner, U Weiss, C Weis, et al.
Biological Psychiatry|June 1, 1996
CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin)C Miller, R Kirchmair, J Troger, et al.
European Journal of Haematology|August 31, 2000
EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparisonM Kopp, H Schweigkofler, B Holzner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 30, 2001
Use of alternative/complementary therapy in breast cancer patients--a psychological perspectiveR Moschèn, G Kemmler, H Schweigkofler, et al.
Pharmacopsychiatry|March 1, 2007
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapineA Hofer, M A Rettenbacher, M Edlinger, et al.
Journal of Neurochemistry|September 13, 2003
Differential effects of phencyclidine application on secretogranin II expression in organotypic slices of rat prefrontal cortexJosef K Hinterhoelzl, Kayvon Salimi, Christian Humpel, et al.
Psychological Medicine|April 18, 2013
Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosisA Riecher-Rössler, J K Rybakowski, M O Pflueger, et al.
The American Journal of Psychiatry|October 2, 2001
Association of olanzapine-induced weight gain with an increase in body fatU Eder, B Mangweth, C Ebenbichler, et al.
Journal of Clinical Psychopharmacology|August 1, 1994
A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatientsC H Stuppaeck, C Geretsegger, A B Whitworth, et al.
International Journal of Clinical Practice|July 14, 2007
Metabolic side effects of antipsychotic medicationA Tschoner, J Engl, M Laimer, et al.
Pageof 15